A minimally invasive procedure that destroys cancer cells by freezing them may be an option other than surgery for treating early-stage kidney cancer. The two methods showed similar 10-year survival rates, with cryoablation showing a lower rate of complications, according to a study published by Morkos et al in the journal Radiology.
About 70% of cases of kidney cancers are diagnosed as stage I. Treatment typically involves surgical removal of the tumor from the kidney—partial nephrectomy. Radical nephrectomy, or removal of the entire kidney, is another surgical option.
Percutaneous cryoablation (PCA) has emerged as an alternative to surgery that destroys the tumor by freezing it. In the procedure, an interventional radiologist inserts a hollow needle into the tumor under imaging guidance. Argon gas circulating through the needle freezes a small volume of tissue, including the tumor and a small amount of normal tissue around it. The tumor dies, and over time it turns into scar tissue that is absorbed by the body.

